<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Infected patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> were treated with the combination of cefmenoxime (CMX) and cefsulodin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CFS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This therapy was done on 74 patients, of whom 38 (51%) had <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo>, 14 (19%) malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 7 (9%) <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 5 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 4 adult T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 4 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 1 <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and 1 histiocytic medullary <z:e sem="disease" ids="C0162460" disease_type="Neoplastic Process" abbrv="">reticulosis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Complicated <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> included 5 cases of <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 41 cases of suspected <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 19 cases of <z:hpo ids='HP_0011947'>respiratory tract infection</z:hpo>, 2 with anal <z:mpath ids='MPATH_612'>abscess</z:mpath>, 1 with <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo> and others </plain></SENT>
<SENT sid="3" pm="."><plain>The obtained results were as follows: Clinical effectiveness of the combination therapy was excellent in 17 cases (23.0%), good in 24 (32.4%) and poor in 33 (44.6%) </plain></SENT>
<SENT sid="4" pm="."><plain>Total clinical efficacy rate was 55.4% </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical efficacy rate was 40% against <z:mpath ids='MPATH_681'>septicemias</z:mpath>, 51.2% against suspected <z:mpath ids='MPATH_681'>septicemias</z:mpath> and 57.9% against <z:hpo ids='HP_0011947'>respiratory tract infections</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Causative pathogens were isolated in only 21 cases (28.4%): <z:mp ids='MP_0001796'>Gram-positive</z:mp> bacteria in 9 cases, <z:mp ids='MP_0001795'>Gram-negative</z:mp> bacteria in 11 and fungus in 1 </plain></SENT>
<SENT sid="7" pm="."><plain>About half of the <z:mp ids='MP_0001795'>Gram-negative</z:mp> bacteria belonged to Pseudomonas sp </plain></SENT>
<SENT sid="8" pm="."><plain>The efficacy rate of this combination therapy against <z:mp ids='MP_0001795'>Gram-negative</z:mp> <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was 72.7% but the rate against <z:mp ids='MP_0001796'>Gram-positive</z:mp> <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were only 33.3% </plain></SENT>
<SENT sid="9" pm="."><plain>Only in 1 case, this combination therapy was discontinued because of <z:e sem="disease" ids="C0011609" disease_type="Disease or Syndrome" abbrv="">drug eruption</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Abnormal laboratory findings were observed in 5 cases: Elevation of BUN in 3, GOT and GPT in 1 and prolongation of activated partial thromboplastin time in 1 </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, this combination therapy of CMX and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CFS</z:e> is useful and safe against <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated by <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
</text></document>